Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million on August 31, 2023. Transaction is subject to Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and Morris, Nichols, Arsht & Tunnell LLP served as legal advisors to EPI Health, LLC and K&L Gates LLP served as legal advisor to Mayne Pharma Group Limited (ASX:MYX).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.38 AUD | -2.23% |
|
-7.01% | -28.78% |
Jul. 02 | Australian Shares Slide as Central Bank Shows Signs of Possible Rate Hike | MT |
Jun. 03 | Swissmedic Grants Mayne Pharma Group Expanded Kapanol Dosage Approvals in Switzerland | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.78% | 240M | |
+24.53% | 45.07B | |
+30.99% | 23.39B | |
+24.13% | 16.08B | |
+21.15% | 14.6B | |
+68.67% | 14.01B | |
-0.05% | 6.79B | |
-13.29% | 6.38B | |
-8.87% | 5.73B | |
+13.53% | 5.64B |
- Stock Market
- Equities
- MYX Stock
- News Mayne Pharma Group Limited
- Mayne Pharma Group Limited agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million.